Compare Novartis AG (NVS) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Tesla, Inc. — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while Tesla, Inc. trades at $379.26 (market cap $1.39T). The key difference: Tesla, Inc. is far larger — about 4.8× Novartis AG's market cap, and Novartis AG pays a 3.17% dividend while Tesla, Inc. pays none. Which is the better fit depends on your goals.
| NVS | TSLA | |
|---|---|---|
Market Cap | $290.25B | $1.39T |
Sector | Health | Consumer Cyclical |
52-Week High | $168.62 | $489.88 |
52-Week Low | $113.50 | $302.63 |
Enterprise Value | $330.27B | $1.36T |
Dividend Yield | 3.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $153.87, showing minimal daily movement with a slight 0.07% gain. The stock exhibits bearish technical signals from moving averages despite a neutral oscillator reading. Fundamentally, the company reported strong Q2 2026 earnings that beat expectations, with revenue of $56.67 billion in 2025 and robust profitability margins, including a net income margin of 23.92%. Recent news highlights successful drug launches offsetting generic competition pressures.
The outlook remains cautiously optimistic as new medicines drive growth, but risks include patent expirations and pipeline trial results. Analyst sentiment is mixed with 68% hold ratings, reflecting balanced views on execution versus competitive threats. Investment appeal hinges on sustained drug innovation and margin stability amid industry headwinds.
Tesla (TSLA) trades at $378.88, down 0.51% with a bearish technical outlook. The stock faces valuation concerns with a P/E of 339 and declining profitability margins, though recent earnings beat expectations. Cash flow remains positive despite heavy capital investments. European regulatory approval for driver-assistance software and German sales growth provide optimism, but competition and slowing auto business present challenges.
Tesla's outlook balances innovation potential against execution risks. The stock offers growth exposure to AI and autonomy but carries premium valuation and competitive pressures. Near-term catalysts include Q2 earnings and robotaxi developments, while margin compression and market sentiment shifts represent key investor risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
